TRCT
ABOS icon

Tower Research Capital (TRC)’s Acumen Pharmaceuticals ABOS Stock Holding History

Tower Research Capital (TRC)’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.74K Buy
2,899
+2,781
+2,357% +$6.87K ﹤0.01% 4114
2026
Q1 		$278 Sell
118
-4,339
-97% -$11.1K ﹤0.01% 4928
2025
Q4 		$9.4K Buy
+4,457
New +$8.84K ﹤0.01% 3900
2025
Q3 		– Sell
-3,631
Closed -$4.21K – 5191
2025
Q2 		$4.21K Sell
3,631
-4,810
-57% -$5.17K ﹤0.01% 4361
2025
Q1 		$9.29K Sell
8,441
-12,183
-59% -$17.4K ﹤0.01% 3797
2024
Q4 		$35.5K Buy
20,624
+16,714
+427% +$40.2K ﹤0.01% 2790
2024
Q3 		$9.7K Sell
3,910
-22,578
-85% -$61.2K ﹤0.01% 3844
2024
Q2 		$64.1K Buy
26,488
+25,078
+1,779% +$79.8K ﹤0.01% 2909
2024
Q1 		$5.71K Sell
1,410
-27,679
-95% -$104K ﹤0.01% 4503
2023
Q4 		$112K Buy
29,089
+26,961
+1,267% +$80K ﹤0.01% 2566
2023
Q3 		$8.83K Sell
2,128
-1,447
-40% -$8.94K ﹤0.01% 4297
2023
Q2 		$17.2K Buy
3,575
+553
+18% +$2.65K ﹤0.01% 3515
2023
Q1 		$12K Sell
3,022
-250
-8% -$1.31K ﹤0.01% 4042
2022
Q4 		$18K Sell
3,272
-4,845
-60% -$32.6K ﹤0.01% 3196
2022
Q3 		$81K Buy
8,117
+4,232
+109% +$24.3K ﹤0.01% 2740
2022
Q2 		$18K Buy
3,885
+1,330
+52% +$5K ﹤0.01% 3880
2022
Q1 		$10K Sell
2,555
-3,968
-61% -$21.6K ﹤0.01% 4266
2021
Q4 		$44K Buy
6,523
+5,828
+839% +$64.1K ﹤0.01% 2852
2021
Q3 		$10K Buy
+695
New +$11.6K ﹤0.01% 4299

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Tower Research Capital (TRC)'s ABOS Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Acumen Pharmaceuticals (ABOS) stake by 2,357% in Q2 2026, buying an estimated $6.87K and bringing the position to 2,899 shares worth $7.74K. The position accounts for ﹤0.01% of the portfolio, ranked #4114.

Tower Research Capital (TRC) first reported a position in ABOS in Q3 2021 and has held it in 19 quarters since. The position peaked at $112K in Q4 2023. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Tower Research Capital (TRC) held 2,899 shares of Acumen Pharmaceuticals worth $7.74K as of Q2 2026.
  • Tower Research Capital (TRC) bought 2,781 Acumen Pharmaceuticals shares in Q2 2026, an estimated $6.87K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4114 holding.
  • Tower Research Capital (TRC) first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Acumen Pharmaceuticals position peaked at $112K in Q4 2023.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.